HealthQuill obesity treatment
Eli Lilly, a US company that forecasts revenue of up to $33.9 billion, plans to build a $2.5 billion plant in Germany to make devices for treating diabetes and obesity.
Drugs Health Pharma

Novo Nordisk buys 3 Catalent sites for $11bn to meet rising demand for Wegovy

HQ Team February 5, 2024: Novo Nordisk will acquire three manufacturing sites in an $11bn deal to expand its production of weightless drugs.

Read More
X